The TLR-specific adjuvants R-848 and CpG-B endorse the immunological reaction of neonatal antigen-presenting cells

Pediatric Research

Volumn 80, Issue 2, 2016, Pages 311-318

  Schüller, Simone ^a   Wisgrill, Lukas ^a   Sadeghi, Kambis ^a   Gindl, Erich ^a   Helmer, Hanns ^b   Husslein, Peter ^b   Berger, Angelika ^a   Spittler, Andreas ^c   Förster Waldl, Elisabeth ^a  

^a UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOKINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 23P40; INTERLEUKIN 4; INTERLEUKIN 6; METHYL CPG BINDING PROTEIN; RESIQUIMOD; TOLL LIKE RECEPTOR AFFECTING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CPG-OLIGONUCLEOTIDE; IMIDAZOLE DERIVATIVE; OLIGODEOXYRIBONUCLEOTIDE; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CELL MATURATION; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; HUMAN; MYELOID DENDRITIC CELL; NEWBORN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREMATURITY; PRIORITY JOURNAL; SURFACE PROPERTY; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; FETUS BLOOD; IMMUNE SYSTEM; IMMUNOLOGY; MALE; METABOLISM; MONONUCLEAR CELL; NORMAL HUMAN; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ANTIGEN-PRESENTING CELLS; CYTOKINES; FEMALE; FETAL BLOOD; FLOW CYTOMETRY; HEALTHY VOLUNTEERS; HUMANS; IMIDAZOLES; IMMUNE SYSTEM; INFANT, NEWBORN; INFANT, PREMATURE; LEUKOCYTES, MONONUCLEAR; MALE; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTORS; UP-REGULATION;

EID: 84983301330     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2016.71     Document Type: Article

References (34)

1. Bonhoeffer J, Siegrist CA, Heath PT. Immunisation of premature infants. Arch Dis Child 2006; 91: 929-35
2. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110(2 Pt 1): 285-91
3. D'Angio CT, Heyne RJ, Duara S, et al.; Premature Infant Vaccine Collaborative. Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants. Pediatr Infect Dis J 2011; 30: 570-4
4. Shinefield H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J 2002; 21: 182-6
5. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007; 7: 379-90
6. Wynn JL, Levy O. Role of innate host defenses in susceptibility to earlyonset neonatal sepsis. Clin Perinatol 2010; 37: 307-37
7. Förster-Waldl E, Sadeghi K, Tamandl D, et al. Monocyte toll-like receptor 4 expression and LPS-induced cytokine production increase during gestational aging. Pediatr Res 2005; 58: 121-4
8. Leja M, Cine E, Rudzite D, et al. Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia. Eur J Gastroenterol Hepatol 2012; 24: 1410-7
9. Garcia AM, Fadel SA, Cao S, Sarzotti M. T cell immunity in neonates. Immunol Res 2000; 22: 177-90
10. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine 2011; 29: 3341-55
11. Cooper CL, Davis HL, Angel JB, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-Treated HIV-infected adults. AIDS 2005; 19: 1473-9
12. Cooper CL, Davis HL, Morris ML, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004; 24: 693-701
13. Mullen GE, Ellis RD, Miura K, et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One 2008; 3: e2940
14. Boraschi D, Aguado MT, Dutel C, et al. The gracefully aging immune system. Sci Transl Med 2013; 5: 185ps8
15. Siegrist CA. Neonatal and early life vaccinology. Vaccine 2001; 19: 3331-46
16. Siegrist CA. Vaccination in the neonatal period and early infancy. Int Rev Immunol 2000; 19: 195-219
17. Schüller SS, Sadeghi K, Wisgrill L, et al. Preterm neonates display altered plasmacytoid dendritic cell function and morphology. J Leukoc Biol 2013; 93: 781-8
18. Lavoie PM, Huang Q, Jolette E, et al. Profound lack of interleukin (IL)-12/IL-23p40 in neonates born early in gestation is associated with an increased risk of sepsis. J Infect Dis 2010; 202: 1754-63
19. Katashiba Y, Miyamoto R, Hyo A, et al. Interferon-and interleukin-12 are induced, respectively, by double-stranded DNA and single-stranded RNA in human myeloid dendritic cells. Immunology 2011; 132: 165-73
20. Levy O, Suter EE, Miller RL, Wessels MR. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 2006; 108: 1284-90
21. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009; 27: 3331-4
22. Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol 2012; 61(Pt 7): 927-34
23. Sharma AA, Jen R, Brant R, et al. Hierarchical maturation of innate immune defences in very preterm neonates. Neonatology 2014; 106: 1-9
24. Philbin VJ, Dowling DJ, Gallington LC, et al. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol 2012; 130: 195-204.e9
25. Wille-Reece U, Flynn BJ, Loré K, et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci USA 2005; 102: 15190-4
26. Wille-Reece U, Flynn BJ, Loré K, et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 2006; 203: 1249-58
27. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol 2005; 174: 7676-83
28. Adams S, Kozhaya L, Martiniuk F, et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res 2012; 18: 6748-57
29. Feyerabend S, Stevanovic S, Gouttefangeas C, et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009; 69: 917-27
30. Sagara I, Ellis RD, Dicko A, et al. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine 2009; 27: 7292-8
31. Cooper CL, Davis HL, Morris ML, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004; 22: 3136-43
32. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-Term seroprotection for up to 5 years. Clin Infect Dis 2008; 46: 1310-4
33. Siegrist CA, Pihlgren M, Tougne C, et al. Co-Administration of CpG oligonucleotides enhances the late affinity maturation process of human antihepatitis B vaccine response. Vaccine 2004; 23: 615-22
34. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997; 185: 1101-11